Qube Research & Technologies LTD Allovir, Inc. Transaction History
Qube Research & Technologies LTD
- $62.3 Billion
- Q2 2024
A detailed history of Qube Research & Technologies LTD transactions in Allovir, Inc. stock. As of the latest transaction made, Qube Research & Technologies LTD holds 78,812 shares of ALVR stock, worth $62,261. This represents 0.0% of its overall portfolio holdings.
Number of Shares
78,812
Previous 107,658
26.79%
Holding current value
$62,261
Previous $81,000
30.86%
% of portfolio
0.0%
Previous 0.0%
Shares
5 transactions
Others Institutions Holding ALVR
# of Institutions
75Shares Held
46.5MCall Options Held
201KPut Options Held
3.1K-
Eco R1 Capital, LLC San Francisco, CA11.3MShares$8.92 Million0.29% of portfolio
-
Octagon Capital Advisors LP New York, NY9.8MShares$7.74 Million1.63% of portfolio
-
Artal Group S.A. Luxembourg, N46.6MShares$5.21 Million0.3% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny3.3MShares$2.6 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.65MShares$2.09 Million0.0% of portfolio
About Allovir, Inc.
- Ticker ALVR
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 93,063,400
- Market Cap $73.5M
- Description
- Allovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, ...